Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease

NeuroImage

Volumn 18, Issue 2, 2003, Pages 416-422

  Ruprecht Dörfler, Petra ^a   Berg, Daniela ^a   Tucha, Oliver ^b   Benz, Peter ^c   Meier Meitinger, Michael ^b   Alders, Gesine L ^b   Lange, Klaus W ^b   Becker, Georg ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Heredity; Parkinson's disease; Substantia nigra hyperechogenicity; Transcranial ultrasound; Vulnerability marker

Indexed keywords

CARBIDOPA; FLUORINE 18;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; MOTOR ACTIVITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RELATIVE; SUBSTANTIA NIGRA;

EID: 0037328470     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-8119(02)00035-6     Document Type: Article

References (29)

1. Becker G., Berg D. Neuroimaging in basal ganglia disorders perspectives for transcranial ultrasound . Mov. Disord. 16:2001;23-32.
2. Becker G., Seufert J., Bogdahn U., Reichmann H., Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 45:1995;182-184.
3. Berg D., Becker G. Perspectives of B-mode transcranial ultrasound. NeuroImage. 15:2002;463-473.
4. Berg D., Becker G., Zeiler B., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 53:1999;1026-1031.
5. Berg D., Grote C., Rausch W.D., et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25:1999;901-904.
6. Berg D., Jabs B., Merschdorf U., Beckmann H., Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol. Psychiatry. 50:2001;463-467.
7. Berg D., Roggendorf W., Schroder U., et al. Echogenicity of the substantia nigra association with increased iron content and marker for susceptibility to nigrostriatal injury . Arch. Neurol. 59:2002;999-1005.
8. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248:2001;684-689.
9. Berg D., Siefker C., Ruprecht-Dorfler P., Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology. 56:2001;13-17.
10. Burn D.J., Mark M.H., Playford E.D., et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 42:1992;1894-1900.
11. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease substantia nigra regional selectivity . Brain. 114:1991;2283-2301.
12. Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E.S. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 48:1987;1077-1082.
13. Forno L.S., Alvord E.C. Jr. The pathology of Parkinsonism. Part I. Some new observations and correlations. Contemp. Neurol. Ser. 8:1971;119-130.
14. Gerlach M., Double K., Riederer P., et al. Iron in the Parkinsonian substantia nigra. Mov. Disord. 12:1997;258-260.
15. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 51:1988;745-752.
16. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease A clinico-pathological study of 100 cases . J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
17. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
18. Lange K.W., Paul G.M., Naumann M., Gsell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J. Neural Transm. 46:(Suppl):1995;423-432.
19. Lange K.W., Robbins T.W., Marsden C.D., James M., Owen A.M., Paul G.M. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl). 107:1992;394-404.
20. Lezak M.D. Neuropsychological Assessment. 1995;Oxford University Press, London.
21. Marder K., Tang M.X., Mejia H., et al. Risk of Parkinson's disease among first-degree relatives a community-based study . Neurology. 47:1996;155-160.
22. Piccini P., Burn D.J., Ceravolo R., Maraganore D., Brooks D.J. The role of inheritance in sporadic Parkinson's disease evidence from a longitudinal study of dopaminergic function in twins . Ann. Neurol. 45:1999;577-582.
23. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease A test of the multifactorial etiologic hypothesis . Neurology. 43:1993;1173-1180.
24. Snow B.J., Tooyama I., McGeer E.G., et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34:1993;324-330.
25. Tanner C.M., Ottman R., Goldman S.M., et al. Parkinson disease in twins an etiologic study . J. Am. Med. Assoc. 281:1999;341-346.
26. Vieregge P., Hagenah J., Heberlein I., Klein C., Ludin H.P. Parkinson's disease in twins a follow-up study . Neurology. 53:1999;566-572.
27. Walter U., Wittstock M., Benecke R., Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J. Neural Transm. 109:2002;191-196.
28. Youdim M.B., Ben. Shachar D., Eshel G., Finberg J.P., Riederer P. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. Adv. Neurol. 60:1993;259-266.
29. Zimmermann, P., Fimm B. A computerized neuropsychological assessment of attention deficits (manual). Wuerselen PsyTest, 1989.